{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:57:19Z","timestamp":1782208639090,"version":"3.54.5"},"reference-count":10,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T00:00:00Z","timestamp":1435276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo Co, Ltd. (Tokyo, Japan)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Two studies in healthy subjects assessed the absorption of edoxaban when delivered to specific locations within the gastrointestinal tract using Enterion capsules. In study 1 (single\u2010dose, 4\u2010way crossover), 8 participants received edoxaban 60\u2009mg as immediate\u2010release (IR) tablets (treatment A), as powder formulation delivered to the distal small bowel (treatment B) or ascending colon (treatment\u2009C), or as an aqueous suspension delivered to the ascending colon (treatment D). In study 2 (single\u2010dose, 2\u2010way crossover), 10 participants received edoxaban 30\u2009mg as IR tablets (treatment E) or in granulate formulation with fumaric acid 50\u2009mg, added to acidify the local gastrointestinal tract and enhance solubility, delivered to the ascending colon (treatment F). Peak and total exposure following targeted drug delivery to the distal gastrointestinal tract were significantly lower than with IR tablet delivery. In study 1, total exposure ratios of treatments B, C, and D compared with A were 14.9%, 7.9%, and 6.1%, respectively. In study 2, relative total exposure was 12.6% for treatment F despite the fumaric acid. Time to peak concentration was longer with higher variability for edoxaban delivered to the distal gastrointestinal tract compared with the IR tablet. These data indicate that edoxaban absorption occurs predominantly in the proximal small intestine.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jcph.540","type":"journal-article","created":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T16:41:40Z","timestamp":1431448900000},"page":"1286-1292","source":"Crossref","is-referenced-by-count":50,"title":["Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule"],"prefix":"10.1002","volume":"55","author":[{"given":"Dolly A.","family":"Parasrampuria","sequence":"first","affiliation":[{"name":"Daiichi Sankyo Pharma Development Edison NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Kanamaru","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Connor","sequence":"additional","affiliation":[{"name":"Quotient Clinical Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Wilding","sequence":"additional","affiliation":[{"name":"Quotient Clinical Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Ogata","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Shimoto","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kunitada","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03064.x"},{"key":"e_1_2_7_3_1","unstructured":"SAVAYSA\u2122 (edoxaban) tablets for oral use. Full prescribing information. Parsipanny NJ: Daiichi Sankyo Inc.;2015."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.046888"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.53"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009351883"},{"key":"e_1_2_7_7_1","article-title":"The effect of rifampin on the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban in healthy subjects","volume":"12","author":"Mendell J","year":"2014","journal-title":"J Thromb Haemost."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-013-0029-0"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.054866"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.4155\/tde.12.34"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1461-5347(00)00311-4"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.540","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.540","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.540","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T14:46:43Z","timestamp":1696603603000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,26]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1002\/jcph.540"],"URL":"https:\/\/doi.org\/10.1002\/jcph.540","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,26]]}}}